{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Salivary+Gland+Carcinoma", "query": { "condition": "Advanced Salivary Gland Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 75, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Salivary+Gland+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T02:17:16.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003182", "title": "Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hope Cancer Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1997-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 2, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003182" }, { "nct_id": "NCT05010629", "title": "9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Salivary Gland Cancer", "Recurrent Salivary Gland Cancer", "Metastatic Cancer", "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glenn J. Hanna", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-09-14", "completion_date": "2027-04-12", "has_results": false, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05010629" }, { "nct_id": "NCT01613768", "title": "Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Salivary Gland Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVC Salivary Gland Cancer" ], "interventions": [ { "name": "eribulin mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2012-05-08", "completion_date": "2017-08-23", "has_results": true, "last_update_posted_date": "2018-09-28", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613768" }, { "nct_id": "NCT00509002", "title": "Iressa Study in Patients With Salivary Gland Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Salivary Gland Cancer" ], "interventions": [ { "name": "Gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2004-05", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509002" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT03517488", "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma" ], "interventions": [ { "name": "XmAb20717", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2018-07-10", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 17, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517488" }, { "nct_id": "NCT04028479", "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Adenocystic Carcinoma", "Anal Cancer", "Appendix Cancer", "Brain Tumor", "Glioblastoma", "Astrocytoma", "Bile Duct Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Bone Cancer", "Synovial Sarcoma", "Chondrosarcoma", "Liposarcoma", "Sarcoma, Kaposi", "Sarcoma,Soft Tissue", "Sarcoma", "Osteosarcoma", "CNS Cancer", "Brain Stem Neoplasms", "Breast Cancer", "Cervical Cancer", "Colorectal Cancer", "Rectal Cancer", "Colon Cancer", "Esophageal Cancer", "Esophagus Cancer", "Cancer of Colon", "Pancreatic Cancer", "Cancer of Pancreas", "Testis Cancer", "Testicular Cancer", "Ureter Cancer", "Renal Cell Carcinoma", "Kidney Cancer", "Gestational Trophoblastic Tumor", "Head and Neck Neoplasms", "Parotid Tumor", "Larynx Cancer", "Tongue Cancer", "Pharynx Cancer", "Salivary Gland Cancer", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Multiple Myeloma", "Non Hodgkin Lymphoma", "Carcinoid Tumor", "Lung Cancer", "Neuroendocrine Tumors", "Mesothelioma", "Thyroid Cancer", "Parathyroid Neoplasms", "Adrenal Cancer", "Small Bowel Cancer", "Stomach Cancer", "Liver Cancer", "Hepatic Cancer", "Melanoma", "Skin Cancer", "Unknown Primary Tumors", "Uterine Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Prostate Cancer", "Vaginal Cancer", "Penile Cancer", "Vulvar Cancer", "Waldenstrom Macroglobulinemia", "Cancer, Advanced", "Thymus Cancer", "Nasopharyngeal Carcinoma", "Multiple Endocrine Neoplasia", "Pheochromocytoma", "Small Cell Carcinoma", "Pulmonary Carcinoma" ], "interventions": [ { "name": "Biomarker Testing (L)", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Treatment (T)", "type": "DRUG" }, { "name": "Patient Reported Outcomes (P)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "OTHER" ], "sponsor": "Taproot Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2021-05-05", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 2, "location_summary": "Idaho Falls, Idaho • Laredo, Texas", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028479" }, { "nct_id": "NCT00023959", "title": "Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "hydroxyurea", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2001-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023959" }, { "nct_id": "NCT00101075", "title": "Title XELOX FOR SALIVARY GLAND CANCERS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2004-10", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101075" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-05-22T02:17:16.275Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" } ] }